Abstract
Doping of horses with recombinant human erythropoietin (rHuEPO) to illegally enhance their endurance capacity in horseracing has been reported during the last years. This leads to increased blood viscosity which can result in sudden death and is of concern for the horse welfare. Additionally, the horse can start production of rHuEPO antibodies, which cross-reacts with endogenous equine EPO and can lead to severe anaemia and even death. In this study, a novel micro-chromatographic method, EPO WGA MAIIA, has been tested for the capability in plasma and urine samples to detect administration of erythropoiesis-stimulating agents, like the rHuEPO glycoprotein varieties Eprex and Aranesp, to horses. After administration of 40 IU Eprex kg−1 day−1 to seven horses during 6 days, the presence of Eprex in horse plasma was detected up to 2–5 days after last injection. In urine samples collected from two horses, Eprex was detected up to 3 days. A single injection of Aranesp (0.39 μg/kg) was detected up to 9 days in plasma and up to 8 days, the last day of testing, in the urine sample. The LC-FAIMS-MS/MS system, with 1 day reporting time, confirmed the presence of Eprex up to 1 day after last injection for six out of seven horses and the presence of Aranesp up to 5 days after last injection in plasma samples. The MAIIA system showed to be a promising tool with high sensitivity and extremely short reporting time (1 h).
Similar content being viewed by others
References
Jelkmann W (2011) Regulation of erythropoietin production. J Physiol 589(Pt 6):1251–1258
Macdougall IC, Ashenden M (2009) Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. Adv Chron Kidney Dis 16(2):117–130
Tablin F, Weiss L (1983) The equine spleen: an electron microscopic analysis. Am J Anat 166(4):393–416
McKeever KH, Agans JM, Geiser S, Lorimer PJ, Maylin GA (2006) Low dose exogenous erythropoietin elicits an ergogenic effect in standardbred horses. Equine Vet J Suppl 36:233–238
Shaskey DJ, Green GA (2000) Sports haematology. Sports Med 29(1):27–38
Piercy RJ, Swardson CJ, Hinchcliff KW (1998) Erythroid hypoplasia and anemia following administration of recombinant human erythropoietin to two horses. J Am Vet Med Assoc 212(2):244–247
Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, Abraham PA (1991) Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 50(6):702–712
Franz SE (2009) Erythropoiesis-stimulating agents: development, detection and dangers. Drug Test Anal 1(6):245–249
Park SS, Park J, Ko J, Chen L, Meriage D, Crouse-Zeineddini J, Wong W, Kerwin BA (2009) Biochemical assessment of erythropoietin products from Asia versus US epoetin alfa manufactured by Amgen. J Pharm Sci 98(5):1688–1699
Jelkmann W (2007) Novel erythropoietic agents: a threat to sportsmanship. Medicina Sportiva 11(2):32–42
Egrie JC, Browne JK (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84(Suppl 1):3–10
Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, Reigner B (2006) Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 1(6):1211–1215
Reichel C (2011) Recent developments in doping testing for erythropoietin. Anal Bioanal Chem 401(2):463–481
Dehnes Y, Lamon S, Lonnberg M (2010) Erythropoietin (EPO) immunoaffinity columns—a powerful tool for purifying EPO and its recombinant analogues. J Pharm Biomed Anal 53(4):1028–1032
Lonnberg M, Dehnes Y, Drevin M, Garle M, Lamon S, Leuenberger N, Quach T, Carlsson J (2010) Rapid affinity purification of erythropoietin from biological samples using disposable monoliths. J Chromatogr A 1217(45):7031–7037
Wide L, Bengtsson C (1990) Molecular charge heterogeneity of human serum erythropoietin. Br J Haematol 76(1):121–127
Wide L, Bengtsson C, Berglund B, Ekblom B (1995) Detection in blood and urine of recombinant erythropoietin administered to healthy men. Med Sci Sports Exerc 27(11):1569–1576
Lasne F (2001) Double-blotting: a solution to the problem of non-specific binding of secondary antibodies in immunoblotting procedures. J Immunol Methods 253(1–2):125–131
Lasne F, de Ceaurriz J (2000) Recombinant erythropoietin in urine. Nature 405(6787):635
Lasne F, Martin L, Crepin N, de Ceaurriz J (2002) Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones. Anal Biochem 311(2):119–126
Kohler M, Ayotte C, Desharnais P, Flenker U, Lüdke S, Thevis M, Völker-Schänzer E, Schänzer W (2008) Discrimination of recombinant and endogenous urinary erythropoietin by calculating relative mobility values from SDS gels. Int J Sports Med 29(01):1–6
Reichel C, Kulovics R, Jordan V, Watzinger M, Geisendorfer T (2009) SDS-PAGE of recombinant and endogenous erythropoietins: benefits and limitations of the method for application in doping control. Drug Test Anal 1(1):43–50
Reichel C, Abzieher F, Geisendorfer T (2009) SARCOSYL-PAGE: a new method for the detection of MIRCERA- and EPO-doping in blood. Drug Test Anal 1(11–12):494–504
Franco Fraguas L, Carlsson J, Lönnberg M (2008) Lectin affinity chromatography as a tool to differentiate endogenous and recombinant erythropoietins. J Chromatogr A 1212(1–2):82–88
Lonnberg M, Andren M, Birgegard G, Drevin M, Garle M, Carlsson J (2012) Rapid detection of erythropoiesis-stimulating agents in urine and serum. Anal Biochem 420(2):101–114
Lasne F, Popot MA, Varlet-Marie E, Martin L, Martin JA, Bonnaire Y, Audran M, de Ceaurriz J (2005) Detection of recombinant epoetin and darbepoetin alpha after subcutaneous administration in the horse. J Anal Toxicol 29(8):835–837
Sato F, Yamashita S, Kugo T, Hasegawa T, Mitsui I, Kijima-Suda I (2004) Nucleotide sequence of equine erythropoietin and characterization of region-specific antibodies. Am J Vet Res 65(1):15–19
Guan F, Uboh CE, Soma LR, Birks E, Chen J, Mitchell J, You Y, Rudy J, Xu F, Li X, Mbuy G (2007) LC-MS/MS method for confirmation of recombinant human erythropoietin and darbepoetin alpha in equine plasma. Anal Chem 79(12):4627–4635
Guan F, Uboh CE, Soma LR, Birks E, Chen J, You Y, Rudy J, Li X (2008) Differentiation and identification of recombinant human erythropoietin and darbepoetin Alfa in equine plasma by LC-MS/MS for doping control. Anal Chem 80(10):3811–3817
Bailly-Chouriberry L, Cormant F, Garcia P, Lönnberg M, Szwandt S, Bondesson U, Popot MA, Bonnaire Y (2012) New analytical method based on anti-EPO monolith column for the rHuEPO purification in horse plasma and urine samples. Analyst, DOI:10.1039/C2AN15662H
Yu NH, Ho EN, Wan TS, Wong AS (2010) Doping control analysis of recombinant human erythropoietin, darbepoetin alfa and methoxy polyethylene glycol-epoetin beta in equine plasma by nano-liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 396(7):2513–2521
Scarth JP, Seibert C, Brown PR, Teale P, Beamon GJ, Pearce CM, Sams RA (2011) UPLC-MS/MS method for the identification of recombinant erythropoietin analogues in horse plasma and urine. Chromatographia 74(7–8):593–608
Lönnberg M (2002) Membrane-assisted isoform immunoassay: separation and determination of protein isoforms. Acta Universitatis Upsaliensis Comprehensive Summaries of Uppsala Dissertations, Faculty of Science and Technology, 691 pp
Lonnberg M, Carlsson J (2001) Chromatographic performance of a thin microporous bed of nitrocellulose. J Chromatogr B 763(1–2):107–120
Lönnberg M, Drevin M, Carlsson J (2008) Ultra-sensitive immunochromatographic assay for quantitative determination of erythropoietin. J Immunol Methods 339(2):236–244
Lonnberg M, Carlsson J (2000) Membrane assisted isoform immunoassay. A rapid method for the separation and determination of protein isoforms in an integrated immunoassay. J Immunol Methods 246(1–2):25–36
Lonnberg M, Carlsson J (2006) Lab-on-a-chip technology for determination of protein isoform profiles. J Chromatogr A 1127(1–2):175–182
Chang Y, Maylin GM, Matsumoto G, Neades SM, Catlin DH (2011) Screen and confirmation of PEG-epoetin beta in equine plasma. Drug Test Anal 3(1):68–73
Acknowledgements
The authors thank Maria Andrén, Malin Drevin, Mikael Lönnberg and Trikien Quach for technical assistance, and the Swedish Foundation for Equine Research, Stockholm, Sweden, and MAIIA Diagnostics, Uppsala, Sweden, for support. The authors are indebted to Dr. Jean-Jacques Garin, veterinary surgeon at FNCF, to the horse farm manager in Coye la Forêt and to the staff who participated in drug administration, sampling and horse care.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lönnberg, M., Bondesson, U., Cormant, F. et al. Detection of recombinant human EPO administered to horses using MAIIA lateral flow isoform test. Anal Bioanal Chem 403, 1619–1628 (2012). https://doi.org/10.1007/s00216-012-5972-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00216-012-5972-0